Clinical practice guidelines for chronic hepatitis C virus infection

Czech version

Authors: P. Urbánek ¹; P. Husa ²; J. Šperl ³; S. Fraňková ³; S. Plíšek ⁴; L. Rožnovský ⁵; P. Kümpel ^6,*
Authors‘ workplace: Interní klinika 1. LF UK a ÚVN Praha ¹; Klinika infekčních chorob LF MU a FN Brno ²; Klinika hepatogastroenterologie, Transplantcentrum, IKEM, Praha ³; Klinika infekčních chorob LF UK a FN Hradec Králové ⁴; Klinika infekčního lékařství LF OU a FN Ostrava ⁵; Infekční oddělení, Slezská nemocnice v Opavě, p. o. ⁶
Published in: Gastroent Hepatol 2017; 71(2): 117-136
Category: Hepatology: Best Practises
doi: https://doi.org/10.14735/amgh2017117

* Pracovní skupina pro virové hepatitidy České hepatologické společnosti ČLS JEP
*Pracovní skupina pro virové hepatitidy Společnosti infekčního lékařství ČLS JEP

Overview

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Sources

1. Pawlotsky JM, Aghemo A, Back D et al. EASL Recommendations on treatment of hepatitis C 2016. J Hepatol 2016. In press. Available from: www.easl.eu/medias/cpg/HCV2016/Summary.pdf.

2. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for disease control and prevention. MMWR Recomm Rep 1998; 47 (RR-19): 1–39.

3. Castéra L, Sebastiani G, Le Bail B et al. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010; 52 (2): 191–198. doi: 10.1016/j.jhep.2009.11.008.

4. Castéra L, Vergniol J, Foucher J et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128 (2): 343–350.

5. Pawlostky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007; 132 (5): 1978–1998.

6. Lawitz E, Mangia A, Wyles D et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368 (20): 1878–1887. doi: 10.1056/NEJMoa1214 853.

7. McQuaid T, Savini C, Seyedkazemi S. Sofosbuvir, a significant paradigm change in HCV treatment. J Clin Transl Hepatol 2015; 3 (1): 27–35. doi: 10.14218/JCTH. 2014.00041.

8. Afdhal N, Zeuzem S, Kwo P et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370 (20): 1889–1898. doi: 10.1056/ NEJMoa1402454.

9. Afdhal N, Reddy KR, Nelson DR et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370 (16): 1483–1493. doi: 10.1056/NEJMoa1316366.

10. Kowdley KV, Gordon SC, Reddy KR et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370 (20): 1879–1888. doi: 10.1056/NEJMoa1402355.

11. Keating GM. Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C. Drugs 2015; 75 (6): 675–685. doi: 10.1007/s40265-015-0381-2.

12. Alqahtani SA, Afdhal N, Zeuzem S et al. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: analysis of phase III ION trials. Hepatology 2015; 62 (1): 25–30. doi: 10.1002/hep.27890.

13. Younossi ZM, Stepanova M, Marcellin P et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, -2, and -3 clinical trials. Hepatology 2015; 61 (6): 1798–1808. doi: 10.1002/hep.27724.

14. Reddy KR, Bourlière M, Sulkowski M et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology 2015; 62 (1): 79–86. doi: 10.1002/hep.27826.

15. Feld JJ, Kowdley KV, Coakley E et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1594–603. doi: 10.1056/ NEJMoa1315722.

16. Zeuzem S, Jacobson IM, Baykal T et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370 (17): 1604–1614. doi: 10.1056/NEJMoa1401561.

17. Poordad F, Hezode C, Trinh R et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370 (21): 1973–1982. doi: 10.1056/NEJMoa1402869.

18. Younossi ZM, Stepanova M, Feld J et al. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial. J Hepatol 2016; 65 (1): 33–39. doi: 10.1016/j.jhep.2016.02.042.

19. Younossi ZM, Stepanova M, Sulkow- ski M et al. Ribavirin-free regimen with sofosbuvir and velpatasvir is associated with high efficacy and improvement of patient-reported outcomes in patients with genotypes 2 and 3 chronic hepatitis C: results from Astral-2 and -3 clinical trials. Clin Infect Dis 2016; 63 (8): 1042–1048. doi: 10.1093/cid/ciw496.

20. Foster GR, Afdhal N, Roberts SK et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015; 373 (27): 2608–2617. doi: 10.1056/NEJM oa1512612.

21. Curry MP, O’Leary JG, Bzowej N et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015; 373 (27): 2618–2628. doi: 10.1056/NEJMoa1512614.

22. Snopková S, Rozsypal H, Aster V et al. Doporučený postup péče o dospělé infikované HIV a postexpoziční profylaxe infekce HIV. [online]. Dostupné z: www.infekce.cz/ DoporART16.htm.